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Abstract
Chronic inflammation associated with hepatitis C virus 
(HCV) infection can lead to disabling liver diseases 
with progression to liver cirrhosis and hepatocellular 
carcinoma. Despite the recent availability of more 
effective and less toxic therapeutic options, in most 
parts of the world the standard treatment consists of 
a weekly injection of pegylated interferon α (IFN-α) 
together with a daily dose of ribavirin. HCV patients 
frequently present circulating non-organ-specific 
autoantibodies demonstrating a variety of staining 
patterns in the indirect immunofluorescence assay 
for antinuclear antibodies (ANA). Between 20% to 
40% of HCV patients treated with IFN-α and ribavirin 
develop autoantibodies showing a peculiar ANA pattern 
characterized as rods and rings (RR) structures. The 
aim of this article is to review the recent reports 
regarding RR structures and anti-rods/rings (anti-
RR) autoantibody production by HCV patients after 
IFN-α/ribavirin treatment. Anti-RR autoantibodies first 
appear around the sixth month of treatment and reach 
a plateau around the twelfth month. After treatment 
completion, anti-RR titers decrease/disappear in half 
the patients and remain steady in the other half. Some 
studies have observed a higher frequency of anti-RR 
antibodies in relapsers, i.e. , patients in which circulating 
virus reappears after initially successful therapy. 
The main target of anti-RR autoantibodies in HCV 
patients is inosine-5’-monophosphate dehydrogenase 
2 (IMPDH2), the rate-limiting enzyme involved in the 
guanosine triphosphate biosynthesis pathway. Ribavirin 
Until recently, in most countries, the standard 
treatment for hepatitis C consisted of weekly injections 
of 180 mcg of interferon alpha (IFN-α) 2a or 1.5 
mcg/kg of IFN-α-2b, typically together with daily 15 
mg/kg ribavirin for 48 to 72 wk[3,4]. IFN has potent 
antiviral activity but does not act directly on the virus 
or replication complex. Instead, it acts by inducing 
IFN-regulated genes (ISGs) that provide a non-
specific antiviral response[5,6]. Ribavirin is a synthetic 
guanosine analogue that acts directly against RNA 
and DNA viruses, probably by inhibiting the virus-
dependent RNA polymerase. As a guanosine analogue, 
ribavirin is intracellularly phosphorylated to generate 
the monophosphate (RMP), diphosphate (RDP), 
and triphosphate (RTP) forms. RMP is a competitive 
inhibitor of inosine-5’-monophosphate dehydrogenase 
2 (IMPDH2), which leads to depletion of GTP required 
for the intracellular synthesis of viral RNA[7]. The 
incorporation of RTP instead of GTP by the virus-
dependent RNA polymerase leads to inhibition of 
viral replication or to the production of defective 
virions. However, RTP has been shown to be a weak 
inhibitor of many viral polymerases[8]. RTP can also 
be incorporated into viral RNA, forming a template 
for pairing to CTP and UTP with equal efficiency. 
The frequency of transitions G→A and A→G in the 
viral genome will then increase, leading to lethal 
mutagenesis[9,10]. Therefore, ribavirin alone has no 
significant effect on HCV, but has a valuable adjuvant 
effect when used in combination with IFN-α therapy[11].
Autoantibodies are immunoglobulins directed against 
self-antigens. They can disturb cellular physiology and 
cause tissue damage by several mechanisms, such as 
(1) blocking membrane receptors; (2) causing cytolysis 
by means of antibody-dependent cytotoxic activity; 
(3) immune complex formation; and (4) complement 
activation, among others[12]. The presence of non-organ-
specific autoantibodies in the sera of HCV patients is 
common. The proportion of ANA-positive HCV patients 
can vary from 7% to 50%, with an average of 20% 
to 30%, depending on the population studied and the 
methodology used. Some HCV patients also present 
autoantibodies normally associated with autoimmune 
liver diseases such as autoimmune hepatitis (AIH) 
and primary biliary cirrhosis[13,14]. Altogether, these 
observations suggest that chronic hepatitis C infection is 
a strong autoimmunogenic condition[15].
Molecular mimicry, imbalance of effector T cells and 
regulatory T cells, and direct action over B lymphocytes 
are possible mechanisms leading to autoimmune 
manifestations of HCV[16]. CD81 on the surface of B 
lymphocytes is a natural ligand for HCV envelope 2 
(E2) protein. B lymphocyte-specific protein CD21, a 
receptor for the complement C3d fragment, is closely 
related to CD81. The B cell threshold for polyclonal 
activation is lowered considerably when HCV E2 coated 
by C3d engages CD81 and CD21, favoring misleading 
B cell activation against autoantigens. In addition, the 
B lymphocyte activating factor (BAFF) is upregulated 
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is a direct IMPDH2 inhibitor and is able to induce the 
formation of RR structures in vitro  and in vivo . In 
conclusion, these observations led to the hypothesis 
that anti-RR autoantibody production is a human model 
of immunologic tolerance breakdown that allows us to 
explore the humoral autoimmune response from the 
beginning of the putative triggering event: exposure to 
ribavirin and interferon. 
Key words: Rods and rings; Autoantibodies; Hepatitis C; 
Ribavirin; Interferon-α
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Core tip: Between 20% and 40% of hepatitis C 
virus patients treated with interferon-α and ribavirin 
develop autoantibodies showing a peculiar antinuclear 
antibodies pattern characterized as rods and rings (RR) 
structures. In those patients, the first appearance of 
anti-RR autoantibodies occurs around the sixth month 
of treatment and reaches a plateau around the twelfth 
month. The main target of anti-RR autoantibodies is the 
inosine-5’-monophosphate dehydrogenase 2 (IMPDH2) 
enzyme, critical in de novo  GTP biosynthesis. In cell 
culture, IMPDH2 inhibition by ribavirin promotes its 
aggregation into RR structures. These observations led 
to the hypothesis that anti-RR autoantibody production 
represents a human model of immunologic tolerance 
breakdown that allows us to explore interesting 
aspects of the humoral autoimmune response from the 
beginning of the putative triggering event.
Keppeke GD, Calise SJ, Chan EKL, Andrade LEC. Anti-rods/
rings autoantibody generation in hepatitis C patients during 
interferon-α/ribavirin therapy. World J Gastroenterol 2016; 
22(6): 1966-1974  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v22/i6/1966.htm  DOI: http://dx.doi.
org/10.3748/wjg.v22.i6.1966
INTRODUCTION
Liver inflammation caused by infection with the 
hepatitis C virus (HCV) remains a major health 
challenge. HCV is transmitted by parenteral contact 
with contaminated blood, frequently through medical 
procedures. HCV is a small RNA virus 40 to 100 nm in 
diameter[1]. It has a single-stranded RNA genome that 
is used directly as messenger RNA in protein synthesis. 
This positive single-stranded RNA is copied to the 
negative strand form, which is used as a template 
for the production of new virus copies. It replicates in 
the cytosol and endoplasmic reticulum of the infected 
cells, usually hepatocytes, producing ten viral proteins. 
Some of these viral proteins inhibit apoptosis and 
others inhibit interferon effects. The pathological effects 
of HCV on the liver are mainly caused by the action of 
the host immune system on infected hepatocytes[2].
during HCV infection. BAFF binds CD19, a transducer 
of activation signal into the cell, adding to the 
production of autoantibodies and cryoglobulins[15,17,18]. 
Since autoantibodies against rods and rings (RR) 
structures have been observed by several laboratories, 
the aim of this article is to review the recent reports 
revealing the main characteristics of anti-RR 
autoantibody production by HCV patients, including 
its clinical relevance and close relationship with IFN-α 
plus ribavirin treatment. The major characteristics of 
RR structures and their molecular constituents are also 
discussed.
HCV TReaTmeNT INDUCes 
aUTOaNTIbODIes agaINsT RR 
sTRUCTURes
About 30% of HCV patients treated with IFN-α plus 
ribavirin (IFN-α/ribavirin) develop autoantibodies 
that recognize cytoplasmic and nuclear structures 
resembling rods and rings (RR) (Figure 1A) in the 
indirect immunofluorescence assay for antinuclear 
antibodies (ANA)[19-21]. Despite occurring in high 
titers, anti-RR autoantibodies have not yet been 
clearly linked with demographic, clinical, or virological 
features[20,22-24]. Instead, by analyzing sequential 
samples from several patients, we showed that 
anti-RR autoantibody production is closely related with 
IFN-α/ribavirin therapy[20,25]. Anti-RR autoantibodies 
initially appeared around the sixth month of treatment 
in nearly half the patients (47%); the anti-RR titers 
also increased during treatment, reaching their highest 
levels towards the end of the standard therapy at 
twelve months. After treatment completion, there 
was a decrease in anti-RR titer in half the patients 
while titers remained steady in the other half[20]. A 
recent publication by Novembrino et al[22] also reported 
anti-RR titer decline after treatment cessation. They 
reported that the frequency of anti-RR increased in 
parallel with therapy duration, with rates of 9%, 38%, 
and 53% at weeks 12, 24, and 48, respectively[22]. 
Since the first reports on autoantibodies against 
RR structures in HCV patients came out, important 
questions have been raised regarding the clinical 
relevance of such autoantibodies. A summary of the 
available data from the literature is presented in Table 1. 
One of the earliest studies by Covini et al[21] found that 
these autoantibodies were more prevalent in patients 
who did not respond to therapy or relapsed (HCV viral 
load increased six months after end of treatment) 
when compared with patients that eliminated the 
virus completely (33% vs 11%, p = 0.037)[21]. The 
publication from Novembrino et al[22] mentioned above 
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Figure 1  Inosine-5'-monophosphate dehydrogenase 2 and cytidine triphosphate synthetase enzymes can aggregate into rods and rings structures. 
A: Representative image of the RR pattern observed in a Euroimmun HEp-2 slide; B-D: HEp-2 cells were cultivated with DON treatment and labeled by indirect 
immunofluorescence with anti-RR-positive HCV serum (B) and rabbit anti-CTPS1 antibody (C). Merged image of panel B and C plus DAPI (D). IMPDH2-based (solid 
arrows), CTPS-based (arrowheads), and mixed RR structures (dotted arrows) can be observed. (A-D) All data and images were obtained in our own laboratory 
from assays performed by Keppeke GD. RR: Rods and rings; DON: 6-diazo-5-oxo-L-norleucine; HCV: Hepatitis C virus; IMPDH2: Inosine-5'-monophosphate 
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samples they examined recognized recombinant 
IMPDH2. Additionally, we performed a sandwich 
ELISA assay where the native antigen was captured 
by affinity-purified polyclonal anti-IMPDH2 antibody 
and found that 37 of the 53 (70%) anti-RR-positive 
samples presented reactivity above the cut-off[25]. 
Finally, double-labeling immunofluorescent studies 
showed that anti-RR autoantibodies label the same RR 
structures as a commercial anti-IMPDH2 antibody, but 
not filamentary structures labeled by an anti-cytidine 
triphosphate synthetase (CTPS) antibody, a critical 
enzyme in pyrimidine biosynthesis that aggregates into 
filamentary RR-like structures[23,27-29]. Altogether, these 
data indicate that IMPDH2 is a major target of anti-RR 
autoantibodies.
RR sTRUCTURes aND THeIR 
FUNCTIONs
Over the last few years, a number of reports have 
described the ability of CTPS and IMPDH2, rate-limiting 
enzymes in the cytidine and guanine nucleotide 
biosynthesis pathways, respectively, to form large 
polymers[23,30-34]. Under certain conditions, these 
enzymes aggregate into structures in the shape of 
rods 3-10 mm in length and rings 2-5 mm in diameter 
(Figure 1). These structures have been designated 
rods and rings (or RR) when the structures are 
composed mainly of IMPDH2, or cytoophidia (Greek 
for “cellular snakes”) and CTPS filaments when the 
structures are composed mainly of CTPS, by different 
laboratories[23,28,29,35]. The first mention of RR-like 
structures dates back to 1987, when Willingham et 
al[36] published that they immunized Balb/c mice with 
Schmidt-Ruppin Rous sarcoma virus-transformed 
reported a higher frequency of anti-RR autoantibodies 
in relapsers when compared with patients that 
achieved sustained virological response (SVR) (56% 
vs 30%, p = 0.0282). Since these two studies found 
a higher prevalence of anti-RR reactivity in relapsers, 
it should be mentioned that relapsing patients are 
usually submitted to a second or third round of 
IFN-α/ribavirin treatment. We discuss above that 
longer exposure to the treatment increases the chance 
that the patient will produce anti-RR autoantibodies. In 
a previous study, we found no association between the 
presence of anti-RR autoantibodies and the response 
to anti-HCV treatment with IFN-α/ribavirin in a cohort 
of 125 patients[20]. This difference between the studies 
may be related to the origin of the cohorts studied and 
SVR rates, since Covini et al[21] and Novembrino et al[22] 
studied Italian patients achieving SVR of approximately 
60%, while we studied Brazilian patients with SVR at 
approximately 30% (Table 1).
The main target of anti-RR autoantibodies has 
been demonstrated in several studies, using different 
methods, to be the IMPDH2 enzyme[19,21,23-26]. In a 2013 
report from Carcamo et al[19], 96% of samples from 
a cohort of 46 Italian patients with anti-RR reactivity 
recognized a 55 kDa band in immunoprecipitation 
(IP) corresponding with IMPDH2 mobility. In the same 
study, they also analyzed an American cohort of 47 
patients; however, only 53% of American patients 
recognized a similar 55 kDa band in IP[19]. When we 
tested a group of Brazilian samples using the same 
methodology, 12 of 15 patients (80%) recognized the 
55 kDa IMPDH2 band[25]. Probst et al[26] developed 
a cell-based indirect immunofluorescent assay with 
HEK293 cells expressing recombinant IMPDH2. Using 
this assay, they found that all 33 anti-RR-positive 
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Table 1  Summary of findings relating the presence of anti-rods and rings autoantibodies to hepatitis C virus treatment outcome
Publication Patient cohort Results Conclusions
Covini et al[21] (2012) Italian cohort: The prevalence of anti-RR antibody was significantly higher in 
REL/NR (33%) than in SVR (11%, P = 0.037)
Higher prevalence of anti-RR 
in RELREL/NR n = 30;
SVR n = 45;
(total = 75)
Keppeke et al[20] (2012) Brazilian cohort: The proportion of NR was equivalent in the 39 patients with 
anti-RR reactivity (77%) when compared with the 86 anti-RR 
negative (64%, P = 0.150)
No association between anti-
RR reactivity and treatment 
outcome
Anti-RR reactivity n = 39;
No anti-RR reactivity n = 86;
(total = 125)
Carcamo et al[19] (2013) United States cohort: n = 47; 
Italian cohort: n = 46; 
(total = 93)
In the United States cohort, NR/REL had significantly higher 
anti-RR titers compared to SVR (about 1:3200 vs 1:100, P = 
0.0016)
Higher titer of anti-RR in REL
In the Italian cohort, REL had significantly higher titers 
when compared to NR and SVR (P = 0.004 and P = 0.015, 
respectively)
Novembrino et al[22] (2014) Italian cohort: Anti-RR reactivity was significantly more frequent in REL (56%) 
than in SVR (30%) or NR (12%) (P = 0.0282)
Higher prevalence of anti-RR 
in RELSVR n = 53;
REL n = 27;
NR n = 8;
(total = 88)
NR: Non-responders, patients who did not respond to therapy; REL: Relapsers, hepatitis C virus viral load increased six months after end of treatment; 
SVR: Sustained virological response, patients that eliminated the virus completely.
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Balb 3T3 cells and obtained a monoclonal antibody 
that labeled cytoplasmic structures very similar to 
RR structures in indirect immunofluorescence. The 
putative antigen/structure was named “nematin” 
due to the worm-like appearance of the observed 
structures.
Enzyme aggregation into non-membrane-bound 
large bodies is a common feature in eukaryotic cells[37]. 
Although it is not known whether all aggregates 
represent functional entities or enzymatically inactive 
storage depots, examples of assembled polymers are 
discussed as a result of: (1) pathologic damage to 
enzymes (e.g., sickle-cell hemoglobin); (2) enhanced 
enzymatic activity (e.g., acetyl-CoA carboxylase); (3) 
formation of structural and functional elements (e.g., 
actin fibers and microtubules); and (4) as a means to 
store catalytic potential (e.g., CTPS filaments)[37]. 
The function of RR structures is still unknown. To 
our knowledge, no study has specifically addressed the 
enzymatic activity state of the IMPDH2 enzyme while 
aggregated into RR. However, four very recent reports 
draw apparently contradicting conclusions regarding 
the enzymatic state of the CTPS enzyme when 
presented in the filamentary cytoophidia form. Three 
of the reports, from Barry et al[38], Aughey et al[39], and 
Noree et al[40], agreed that the aggregation of CTPS 
into cytoophidia downregulates enzymatic activity[38-40]. 
Strochlic et al[41], on the other hand, demonstrated 
that CTPS within the cytoophidia structures is 
catalytically active during Drosophila oogenesis[41]. 
Thus, the current hypothesis is that the assembly 
and disassembly of RR/cytoophidia structures allows 
for a highly sensitive control of enzymatic activity 
by keeping enzymes in active/inactive forms. This 
could be an important mechanism of regulation of the 
indispensable GTP/CTP biosynthesis pathways. 
The observation that some RR structures disas-
semble after injection of anti-IMPDH2 antibody into live 
cells indicates that IMPDH2 molecules are the major 
building blocks of IMPDH2-based RR structures[27]. 
However, it also indicates that the binding among 
IMPDH2 molecules to form RR structures is not 
very strong, allowing its disassembly by putative 
chemical tension, allosteric interactions, or other 
unknown mechanisms generated by the binding of 
several antibodies. These observations reinforce the 
hypothesis that assembly and disassembly of RR 
structures represent highly sensitive maneuvers to 
control enzymatic activity as described in the previous 
paragraph[27].
Aggregation of IMPDH2 vs CTPS
Several publications demonstrated the ability of 
IMPDH2 and CTPS to aggregate into large filamentary 
structures; however, those studies were focused 
on only one of these enzymes at a time[23,30-32]. 
While studying both enzymes simultaneously, we 
demonstrated the independent formation of IMPDH2-
based (structures composed mainly of IMPDH2) 
and CTPS-based (structures composed mainly of 
CTPS) filamentary structures within the same cell. 
We also reported that after treatment with glutamine 
antagonist 6-diazo-5-oxo-L-norleucine (DON), both 
enzymes can interact in the formation of “mixed” RR 
structures that display a mosaic of IMPDH2 and CTPS 
aggregation (Figure 1B-D)[29]. 
IMPDH is involved in purine biosynthesis, catalyzing 
the nicotinamide adenine dinucleotide (NAD+)-
dependent oxidation of inosine-5’-monophosphate 
(IMP) to xanthosine-5’-monophosphate (XMP), which 
is then converted into guanosine triphosphate (GTP), 
a precursor of the guanine nucleotide[42,43]. Humans 
express two distinct versions of IMPDH with 84% 
sequence resemblance and similar kinetic properties, 
encoded by different genes: IMpDH1 and IMpDH2[43]. 
Both IMPDH1 and IMPDH2 are expressed constitutively 
in most tissues, however IMPDH2 is highly expressed 
in cancer cells and proliferating tissues[44-46]. Therefore, 
IMPDH has been targeted by immunosuppressive 
drugs such as mycophenolate (mycophenolic acid or 
MPA). CTPS is involved in pyrimidine biosynthesis, 
catalyzing the final step in the biosynthesis of the 
nucleotide cytosine by converting uridine triphosphate 
(UTP) into cytidine triphosphate (CTP)[47,48]. In humans, 
two versions of CTPS are encoded by different genes: 
the CTpS gene for the enzyme CTPS1 and the CTpS2 
gene for the enzyme CTPS2. Both are expressed 
constitutively in all tissues, as they are related to 
cellular growth and development, but have been shown 
to be overexpressed in cancer tissues, making them 
candidate targets for anti-cancer chemotherapy[48,49].
IMPDH2 and CTPS seem to respond differently 
to conditions that induce their aggregation into 
RR/cytoophidia, such as the increase in intracellular 
concentrations of nucleotides[32,33]. In the presence of 
excess guanosine, IMPDH2-based RR formed by DON 
disassembled, but not CTPS-based cytoophidia[29]. This 
indicates that there are likely two distinct aggregation 
models for IMPDH and CTPS. RR and cytoophidia show 
very similar characteristics of formation and behavior, 
such as the morphological characteristics of rods and 
rings predominantly localizing to the cytoplasm and 
occasionally being observed within the nucleus as 
shorter, thinner structures. However, it has not yet 
been determined if the mechanisms that regulate the 
aggregation of each enzyme into RR/cytoophidia are 
related or not. While some progress has been made in 
the study of the enzymatic activity of CTPS filaments, 
the enzymatic state of IMPDH2 in its aggregated form 
is still totally unknown.
TOleRaNCe bReakDOwN: THe aNTI-RR 
Case
Self-immune tolerance breakdown with autoantibody 
production is a multifactorial process that involves 
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intrinsic and extrinsic aspects. Intrinsic aspects depend 
on individual characteristics and certain abnormalities 
which may involve genes related to the major 
histocompatibility complex and several molecules 
involved in the control of the innate and adaptive 
response, as well as the hormonal environment. 
Extrinsic aspects could be various xenobiotics such as 
bacterial and viral infections or physical and chemical 
agents such as UV light exposure, pesticides, and 
drugs (including medications[50]). Improper nutrition 
and lack of exercise are also possible contributors[51,52].
The generation of anti-RR/IMPDH2 autoantibody 
appears to depend on inhibition of the target enzyme by 
treatment with ribavirin. In a previous study from our 
laboratory, none of 166 treatment-naïve HCV patients 
showed anti-RR reactivity. In fact, anti-RR/IMPDH2 
antibodies were exclusively observed in patients who had 
undergone IFN-α/ribavirin therapy[20]. The absence of 
anti-RR in HCV patients prior to IFN-α/ribavirin therapy 
was also described in other studies[21,22]. However, 
it is possible that the immunological abnormalities 
associated with HCV infection and administration of 
IFN-α that stimulate the host immune system establish 
the conditions for ribavirin to act as an activator for 
the breakdown of tolerance with generation of anti-
IMPDH2 autoantibodies (Figure 2). Indeed, we noticed 
that systemic lupus erythematosus patients treated 
with mycophenolate mofetil, an inhibitor of IMPDH2, 
do not develop anti-RR antibodies, except in extremely 
rare cases[20,53,54]. In other words, the production of 
autoantibodies to IMPDH2 is unlikely to result from the 
inhibition of IMPDH2 and formation of RR alone (Figure 
2)[54].
In view of the facts that anti-RR autoantibodies 
primarily target IMPDH2, that inhibition of IMPDH2 by 
ribavirin leads to its aggregation into RR structures, 
and that HCV patients undergoing ribavirin treatment 
produce anti-RR/IMPDH2 antibodies, we hypothesize 
that this represents a human model of immunologic 
tolerance breakdown followed by autoantibody 
production. We explored such a model, aiming to 
determine the temporal kinetics of the humoral autoim-
mune response to IMPDH2 in patients from the onset 
of treatment with IFN-α/ribavirin. We demonstrated 
that regarding titer, avidity maturation, and isotype 
levels, the humoral autoimmune response to IMPDH2 
resembled that of a conventional humoral response to 
infectious agents, although at a considerably slower 
pace in titer increase and avidity maturation, as well as 
in isotype class switch, since these changes occurred 
over months in contrast to a time frame of weeks in 
the case of an infectious challenge[25,55]. The temporal 
kinetics of the humoral autoimmune response is not 
readily accessible in human diseases, because we do 
not know when the triggering event occurs. The model 
of anti-RR/IMPDH2 autoantibody induced by ribavirin 
treatment provides a unique opportunity to study 
this aspect of the autoimmune response in humans. 
This difference may be related to the peculiarities in 
the adjuvant milieu in autoimmune and infectious 
diseases. The conventional infectious process is fueled 
by the strong adjuvant effect of the innate immune 
response associated with the inflammation caused by 
exposure to pathogen-associated molecular patterns 
(PAMPs) related to infectious agents. In the scenario 
of an autoimmune response, on the other hand, 
these elements are lacking or are present in minor 
proportions, thus possibly conveying different kinetics of 
the specific autoimmune response against self-antigens. 
Another element that might contribute to a slower pace 
in the maturation of the autoimmune humoral response 
is the existence of an array of counter-regulatory 
mechanisms that contribute to the maintenance of 
tolerance to self, including regulatory T and B cells. 
1971 February 14, 2016|Volume 22|Issue 6|WJG|www.wjgnet.com




IFN-α + ribavirin therapy
IMPDH2 aggregates into RR in the patient cells
Turnover cellular RR and present to host immune system
IFN-α further stimulates autoimmune response to RR
Anti-RR antibody levels 
increase
Figure 2  Anti-rods and rings autoantibody production in patients with chronic hepatitis C virus infection. Ribavirin therapy leads cells to present RR 
structures, while interferon-α stimulates the host immune system. These factors, plus others yet to be confirmed, could contribute to the tolerance breakdown with 
autoantibody production against RR structures, whose levels increase during treatment. RR: Rods and rings; HCV: Hepatitis C virus; IFN: Interferon.
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ClINICal ReleVaNCe OF aNTI-RR 
aUTOaNTIbODY 
The possible clinical impact of anti-RR antibodies 
has been investigated by several laboratories, but 
no association has been found with disease severity, 
clinical evidence of autoimmunity, viral load or strain, 
or intensity of liver inflammation and injury[20,22-24]. 
On the other hand, as outlined above, some studies 
indicate that the presence of anti-RR autoantibodies, 
especially at high titer, are more frequently observed 
in HCV-treated patients classified as relapsers. This 
association was observed in the cohorts of Italian 
and American patients[19,21,22], but no such trend was 
observed in the Brazilian cohort[20]. These observations 
could suggest that the presence of anti-RR auto-
antibodies indicates a higher chance for poor response 
to IFN-α/ribavirin therapy, and might support interruption 
of the treatment and a switch to the new protease 
inhibitors available for HCV therapy. 
However, we emphasize that there is no established 
evidence for this reasoning. The association observed 
in the Italian and American cohorts is marginally 
significant from a statistical point of view, and there 
is considerable overlap between responders and 
relapsers with respect to the presence of anti-RR 
reactivity. In addition, no such association was found 
in the larger Brazilian cohort. In fact, we propose 
that the marginal association observed in some 
cohorts may operate from a different perspective. 
The production of autoantibodies against RR/IMPDH2 
is stimulated by IFN-α/ribavirin treatment, save rare 
exceptions[53]. Ribavirin has been shown to induce 
IMPDH2 to aggregate into RR structures in vitro[23,29] 
and in vivo (Keppeke and Andrade, unpublished data). 
The strict association between anti-RR reactivity and 
IFN-α/ribavirin treatment in HCV patients strongly 
suggests that the ribavirin-induced IMPDH2 aggregate 
is the triggering immunogen in this drug-induced 
autoimmune reaction. It is therefore conceivable that 
longer exposure to the treatment would result in a 
higher chance of anti-RR autoantibody development. 
Unpublished observations from our laboratory show 
that up to approximately 70% of the patients treated 
for a second or third time present positive anti-RR 
reactivity as opposed to an approximately 40% 
frequency in patients treated for the first time. This 
finding adds strength to the hypothesis that longer 
treatment means a higher chance to produce anti-RR 
autoantibodies. Relapsers are patients that often need 
to receive successive rounds of treatment with IFN-α/
ribavirin. In view of this reasoning, we propose that 
the higher proportion of anti-RR reactivity in relapsers 
observed in the Italian cohort might be attributed 
to the longer period of exposure to ribavirin in these 
patients. This hypothesis must be appropriately 
challenged in prospective follow-up studies with a 
large and heterogeneous cohort of patients. In the 
meantime, it might be appropriate to closely follow 
anti-RR-positive patients with more frequent viral load 
measurements. 
In conclusion, the autoantibody response against 
IMPDH2 elicited by ribavirin treatment in hepatitis 
C patients has allowed us to explore interesting 
aspects of immunological tolerance breakdown in 
humans from the beginning of the triggering event. 
In addition, anti-RR autoantibodies turned out to be 
invaluable tools in the investigation of the intriguingly 
large cytoplasmic and nuclear structures known as 
rods and rings. The molecular constitution of these 
RR/cytoophidia structures thus far appears to be 
largely based on the IMPDH2 and/or CTPS enzymes. 
Our laboratory and others have had the opportunity 
to verify that the RR structures may occur in many 
physiological and pathological instances. Currently, our 
efforts are dedicated to understanding the biological 
significance and the biochemical mechanisms involved 
in the process of aggregation of enzymes, especially 
the IMPDH2 enzyme, into RR structures. Future studies 
should also investigate why IMPDH2 is preferentially 
targeted by the immune system of HCV patients 
under IFN and ribavirin therapy, the role of IMPDH2 
aggregation into RR filaments in this phenomenon, 
and to establish animal models for anti-RR tolerance 
breakdown as observed in HCV patients.
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